Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.
about
Risk definition and management strategies in retinoblastoma: current perspectivesChemotherapy in Retinoblastoma: Current ApproachesIntra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D RetinoblastomaRisk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapySarcomas in hereditary retinoblastomaFocal laser treatment in addition to chemotherapy for retinoblastoma.Germ-line and somatic DICER1 mutations in pineoblastoma.Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admissionCombined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern CaliforniaSecond nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.Models and discovery strategies for new therapies of retinoblastoma.Management of retinoblastoma in children: current status.Retinoblastoma: achieving new standards with methods of chemotherapy.New Translational Research in the Medical Management of Orbital Melanoma.Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center.Pediatric second primary malignancies after retinoblastoma treatment.Lack of vincristine infiltrates in patients with retinoblastoma receiving chemotherapy by peripheral intravenous lines.Second Primary Rhabdomyosarcoma in Nonhereditary Unilateral Retinoblastoma Not Treated with RadiotherapyAcute lymphoblastic leukemia as second primary tumor in a patient with retinoblastoma.Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina.Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma.Injectable hydrogels for ophthalmic applications.Monte Carlo study for designing a dedicated "D"-shaped collimator used in the external beam radiotherapy of retinoblastoma patients.A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.Focal laser treatment in addition to chemotherapy for retinoblastoma
P2860
Q26849675-161EA293-C33F-4551-A60F-7436AC1423F9Q28075246-5805B081-4587-4C74-96B8-5484F9469718Q28552363-A3E5EF54-2228-4666-A6BB-FBC71A1C3D7DQ34260518-FF86ECFD-AC64-4E74-9AD7-61FB296CFB4DQ34433701-FFD1D619-74D1-4275-8481-FF16DC522D9AQ34557627-B8026815-FA1C-4F8D-85FF-6A48C27A271AQ35240049-B1820745-D637-4E7B-8986-D4AE876336E9Q35981061-414FF23B-D723-437E-AADC-77DF96E8F0F0Q36212064-4F66FD04-F110-466D-AC97-B72D51651411Q36321693-79CDA967-A3F0-450A-BFE1-AF44A8DA3596Q36615019-ADF29A3F-D620-4F8A-A866-3DBDD53B0DABQ36843419-B536E38B-95E9-47C4-A325-996DA5EA9332Q37646416-8931934A-8F11-4E24-BAF9-41BCC1AB2D75Q38045274-3DE9E650-FA77-406D-9899-494BD543A316Q38083299-83C1206E-DCB5-4D78-8F75-BFDA8B82B533Q38368017-5E06F7CE-CF28-4FD7-9CA5-98166A850CB1Q38397827-3BAABA1E-8EE4-49C4-90F8-6307E144DE69Q38766811-3CE613F4-3C6C-470A-816B-56F4CB702DCDQ39055366-EBEBCDC9-A064-4AA6-97C7-B51831D9BE80Q39448081-D445F0CA-4988-484C-83A3-4297228E1180Q40943598-5508683C-5F35-4D3A-8EDA-58C05E88E1B5Q41269037-03397641-ABF3-4209-8C91-59AC1F9FC3FEQ42341489-267E46CE-6306-48B8-A0DC-9AFBE22D00EFQ42432637-3F3A05A1-EEE0-4EA9-8543-A98971A7417FQ44219750-91AEDD99-0D57-45EE-A3AE-70B029B691B0Q47647048-1DF9F81A-8136-475D-9171-FE8B4E8DD893Q50072638-5297BF89-6E5C-4C02-9F7F-DD0152695BA8Q50737160-3C5C3EAB-316A-4965-ACEB-48C49562C23AQ54773992-653A7CB4-BF39-4869-AE56-75423C18F4F7Q55021792-A11DAFFD-E4C1-46F2-906F-C4FC23C9DC55Q58494225-339C3C35-05DB-4107-AC1E-7484D520067D
P2860
Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@en
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@nl
type
label
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@en
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@nl
prefLabel
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@en
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@nl
P2093
P2860
P356
P1476
Second malignant neoplasms fol ...... th intraocular retinoblastoma.
@en
P2093
Ann Leahey
Anna T Meadows
Carol L Shields
Kiran Turaka
P2860
P304
P356
10.1002/PBC.23278
P577
2011-08-08T00:00:00Z